PAX5 and acute lymphoblastic leukemia: In support of this notion, PAX5 deletions were found in over 50% of BCR::ABL1 and 18% of TCF3::PBX1 B-ALL cases (3, 8, 10), and were enriched in Ph-like B-ALL patients as well (14).